Advertisement
Canada markets close in 5 hours 27 minutes

  • S&P/TSX

    21,782.76
    +54.21 (+0.25%)
     

  • S&P 500

    5,038.53
    +20.14 (+0.40%)
     

  • DOW

    38,080.80
    +177.51 (+0.47%)
     

  • CAD/USD

    0.7296
    +0.0015 (+0.20%)
     

  • CRUDE OIL

    79.05
    +0.05 (+0.06%)
     

  • Bitcoin CAD

    80,382.18
    +1,650.69 (+2.10%)
     

  • CMC Crypto 200

    1,261.16
    -9.58 (-0.75%)
     

  • GOLD FUTURES

    2,308.40
    -2.60 (-0.11%)
     

  • RUSSELL 2000

    1,990.00
    +9.77 (+0.49%)
     

  • 10-Yr Bond

    4.6410
    +0.0460 (+1.00%)
     

  • NASDAQ

    15,708.10
    +102.62 (+0.66%)
     

  • VOLATILITY

    15.50
    +0.11 (+0.71%)
     

  • FTSE

    8,171.25
    +50.01 (+0.62%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6821
    +0.0028 (+0.41%)
     
MARKETS LIVE BLOG:

STOCKS TRADE HIGHER AS RATE-HIKE FEARS FADE, WITH APPLE ON DECK

Wall Street bracing for drop in revenue, potentially hefty pullback in iPhone sales in China

Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation

PR Newswire
·1 min read

ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. Further discussion is included in footnote 2 of the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2023.

Ampio Pharmaceuticals Logo. (PRNewsFoto/Ampio Pharmaceuticals, Inc.) (PRNewsfoto/Ampio Pharmaceuticals, Inc.)
Ampio Pharmaceuticals Logo. (PRNewsFoto/Ampio Pharmaceuticals, Inc.) (PRNewsfoto/Ampio Pharmaceuticals, Inc.)

For more information, contact:
Ampio Pharmaceuticals, Inc.
Michael A. Martino
Chief Executive Officer
mmartino@ampiopharma.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-received-audit-opinion-with-going-concern-explanation-302107593.html

SOURCE Ampio Pharmaceuticals, Inc.